An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi(Warneford Hospital), Catherine J. Harmer(Warneford Hospital), Philip J. Cowen(University of Oxford), Toby Pillinger(King's College London), Rachel Upthegrove(Birmingham and Solihull Mental Health NHS Foundation Trust), Amanda Adler(Oxford Centre for Diabetes, Endocrinology and Metabolism), Maxime Taquet(Oxford Health NHS Foundation Trust), Robert A. McCutcheon(Oxford Health NHS Foundation Trust), Marco Solmi(University of Ottawa), Ivan Koychev(John Radcliffe Hospital), Oliwia Dziwisz(Warneford Hospital), Ana Ghenciulescu(Warneford Hospital)
Cited by 58
Related Papers
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies
|Molecular Psychiatry|2021|3.6k
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
|The Lancet Psychiatry|2021|2.2k
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls
|World Psychiatry|2017|1.7k
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
|The Lancet Psychiatry|2019|1.5k